Suppr超能文献

巴雷特食管腺癌的组织病理学诊断。

Histopathological diagnosis of adenocarcinoma in Barrett's esophagus.

机构信息

Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology; Department of Pathology, Tokyo Metropolitan Geriatric Hospital.

出版信息

Dig Endosc. 2014 May;26(3):322-30. doi: 10.1111/den.12160. Epub 2013 Aug 25.

Abstract

The present review describes the histological markers of Barrett's esophagus (BE) that make it possible to distinguish between Barrett's carcinoma (BC) and gastric carcinoma. With regard to high-grade dysplasia, the indications for endoscopic resection (ER) or major surgery for management of BC cannot be decided on the basis of biopsy histology, and the choice between them should be made according to BC invasion depth. Therefore, we recommend that the term 'well-differentiated tubular adenocarcinoma' be used rather than 'high-grade dysplasia' (intraepithelial neoplasia). High-grade dysplasia is regarded as BC in Japan and other countries such as Germany. Such lesions should not be treated by endoscopic ablation but by ER, because components of invasive carcinoma are frequently present in the mucosa and submucosa, and knowledge obtained from ER samples is needed for additional therapy. Further studies on the relationship between the incidence of nodal metastasis and mucosal depth in mucosal BC are needed to decide the indications for ER. Suchstudies should involve subserial microscopic examination of slices 2-3 mm thick. To resolve the issue of regression of high-grade dysplasia, international experts in gastroenterological pathology need to conduct histopathological reviews of the first and last samples taken from such cases, as there are large differences between North American, European, and Japanese pathologists in the criteria used for histological diagnosis of dysplasia and adenocarcinoma without clear invasion, and both interobserver and intraobserver variations have been reported. Future studies will need to focus on which carcinomas are curable by ER.

摘要

本文综述了 Barrett 食管(BE)的组织学标志物,这些标志物可用于区分 Barrett 癌(BC)和胃癌。对于高级别异型增生,内镜下切除(ER)或主要手术治疗 BC 的适应证不能仅根据活检组织学来决定,应根据 BC 的浸润深度来选择。因此,我们建议使用“分化良好的管状腺癌”而非“高级别异型增生”(上皮内肿瘤)来描述这种情况。在日本和德国等其他国家,高级别异型增生被视为 BC。这些病变不应通过内镜消融治疗,而应通过 ER 治疗,因为在黏膜和黏膜下层中经常存在浸润性癌的成分,并且需要从 ER 样本中获得的知识来进行额外的治疗。需要进一步研究黏膜 BC 中黏膜深度与淋巴结转移发生率之间的关系,以确定 ER 的适应证。此类研究应涉及对 2-3 毫米厚切片的亚系列显微镜检查。为了解决高级别异型增生的消退问题,需要由胃肠病学病理学的国际专家对这些病例的首次和末次样本进行组织病理学复查,因为北美、欧洲和日本病理学家在用于诊断无明确浸润的异型增生和腺癌的组织学标准方面存在较大差异,并且已经报道了观察者间和观察者内的变异。未来的研究将需要关注哪些癌可以通过 ER 治愈。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验